Annette Marcantonio
Corporate Officer/Principal chez JASPER THERAPEUTICS, INC.
Profil
Annette Marcantonio is currently the Vice President of Clinical Operations at Jasper Therapeutics, Inc. Prior to this, she held the same position at Aimmune Therapeutics, Inc. from 2016 to 2020.
She received her undergraduate degree from Loyola Marymount University.
Postes actifs de Annette Marcantonio
| Sociétés | Poste | Début |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Corporate Officer/Principal | 02/08/2023 |
Anciens postes connus de Annette Marcantonio
| Sociétés | Poste | Fin |
|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2020 |
Formation de Annette Marcantonio
| Loyola Marymount University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JASPER THERAPEUTICS, INC. | Finance |
| Entreprise privées | 1 |
|---|---|
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |